Skip to content
★ Sign in to follow
China Resources Double-Crane Pharmaceutical Co.,Ltd. logo

China Resources Double-Crane Pharmaceutical Co.,Ltd. Stock: price and insider trades · China

华润双鹤

CN·Mcap CN¥17.1BHealth Care

No insider purchase over the last 90 days. The latest, by 余顺坤, was filed 15 Jul 2024.

China Resources Double-Crane Pharmaceutical Co.,Ltd.: what insiders have been doing

Every trade that managers of China Resources Double-Crane Pharmaceutical Co.,Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector and is based in Donghu Subdistrict, People's Republic of China. Nothing new has been filed by managers of China Resources Double-Crane Pharmaceutical Co.,Ltd. in twelve months, the latest record being from 15 July 2024.

The full history, which starts in 2022, counts 3 purchases against no sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Key facts

Headquarters: Donghu Subdistrict, People's Republic of China

Source: Wikidata (CC0).

Insider Decl.
3
Thresholds
n/a
Buy Volume
€66,818
3 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 15 Jul 2024 · 846 days ago · €22k
    +10.6%
    Entry CN¥17.42 · Close at T+365 CN¥19.27
  • Filed 20 Dec 2022 · 1419 days ago · €29k
    -13.9%
    Entry CN¥21.79 · Close at T+365 CN¥18.76
  • Filed 16 Dec 2022 · 1423 days ago · €16k
    -16.5%
    Entry CN¥22.91 · Close at T+365 CN¥19.12

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 1,881 of 26,897 companies
76.9
score / 100
Value
76
Quality
78
FCF yld5.1%
Earn yld9.6%
EV/EBITDA6.7x
ROE13%
Gross mgn58%
Net mgn15%
Debt/EBITDA0.4x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥16.44
Analyst consensus
2 analysts
·
CN¥22.50Target CN¥24.30(+48%)CN¥26.10
Income statement
RevenueCN¥11B
Gross profitCN¥6.4B58% margin
EBITDACN¥2.7B25% margin
Net incomeCN¥1.6B14.9% margin
Valuation
PER (trailing)10.5x
P/Book1.4x
Beta-0.07
Balance sheet & cash
Market capCN¥17.1B
Total debtCN¥1.2B
Free Cash FlowCN¥869.9M
Debt / Equity9%
Profitability & ownership
ROE13.2%
ROA5.6%
% insiders62.7%
% institutions1.6%
Last declaration on 15 July 2024
Declarations3 total
  • ▲
    独立董事Executives
    174,400 CNY15SSE
    10,000 shares100.0% of flowA股XSHGSSE:173000008213711140
    Canonical exit: 13 Oct 2024 (T+90)
  • ▲
    高级管理人员Executives
    212,200 CNY31SSE
    10,000 shares100.0% of flowA股XSHGSSE:173000006147079650
    Canonical exit: 20 Mar 2023 (T+90)
  • ▲
    高级管理人员Executives
    119,950 CNY19SSE
    5,000 shares100.0% of flowA股XSHGSSE:173000006142148640
    Canonical exit: 16 Mar 2023 (T+90)

3 of 3 declarations

About China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double Crane is a Chinese company operating in the healthcare and pharmaceutical sector, specializing in the research, development, and manufacturing of pharmaceuticals. It is listed on the Shanghai Stock Exchange.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations